Dr. Hanneke W.M. van Laarhoven Medische Oncologie Academisch Medische Centrum Blik op de toekomst: lopende en geplande DOCG studies • Neoadjuvante chemoradia1e: surgery when needed (preSANO) • Neoadjuvante chemoradia1e: targeted treatment (TRAP) • Neoadjuvante/defini1eve chemoradia1e: surgery if possible (TOR) • Defini1eve chemoradia1e: dosisintensifica1e (ART-‐DECO) • Dataregistra1e (POCOP) preSANO pre-‐ Surgery As Needed for Oesophageal carcinoma A single-‐arm feasibility trial Primary endpoint • Correla1on between the clinical response during CRE-‐I and CRE-‐II and the final pathological response in the resec1on specimen Secondary endpoints • Serious complica1ons during endoscopic and endosonographic 1ssue sampling • R0-‐resec1on rates for all included pa1ents that undergo resec1on TRAP Chemoradia1on, TRAstuzumab and Pertuzumab in resectable HER2+ esophageal carcinoma A single arm feasibility study Primary endpoint • Withdrawal rate from surgery Secondary endpoints • pCR • Toxicity • Post-‐opera1ve complica1ons TOR Chemoradiotherapy followed by resec1on for pa1ents with gevolgd a T4b oesofagus carcinoma Primary endpoint • R0 resec1on (≥ 80% ) Secondary endpoints • Post-‐opera1ve complica1ons • Mortality • Quality of life ART-‐DECO A Randomized Trial of Dose Escala1on in defini1ve Chemoradiotherapy for pa1ents with Oesophageal cancer Landelijk Pla[orm Radiotherapie voor Gastro Enterologische tumoren Primary endpoint • Local recurrence rate (≥ 15% difference) Secondary endpoints • Grade 3-‐4 toxicity • Survival POCOP Prospec1ve Observa1onal Cohort Study of Oesophageal-‐gastric cancer Pa1ents Acknowledgments • Joel Shapiro, Bas Wijnhoven, Jan van Lanschot (preSANO) • Maarten Anderegg, Mark van Berge Henegouwen (TOR) • Maarten Hulshof (ART-‐DECO) • Leonie Haverkamp, Jelle Ruurda (Oesofagus/maag parel)
© Copyright 2024 ExpyDoc
